Skip to main content
Clinical Trials/NCT06060002
NCT06060002
Not yet recruiting
Not Applicable

Role of Prophylactic Biliary Stent in Reducing the Recurrence of Choledocholithiasis and Biliary Complications After Stone Clearance in Patients Awaiting Cholecystectomy-A Multicentric Randomized Controlled Trial (STONE Trial)

Asian Institute of Gastroenterology, India0 sites480 target enrollmentSeptember 30, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Choledocholithiasis
Sponsor
Asian Institute of Gastroenterology, India
Enrollment
480
Primary Endpoint
To compare the CDL recurrence rate between the 2 groups
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

We planned this multicenter randomized controlled trial to study the role of a prophylactic biliary stent in recurrence of stones and biliary complications in patients awaiting cholecystectomy after biliary stone clearance

Detailed Description

Patients with cholelithiasis can have presence of concomitant choledocholithiasis (CDL) in upto 30%. These stones may remain asymptomatic or cause obstructive jaundice and complications like cholangitis and pancreatitis. In situations where there is a failure of CDL clearance during endoscopic retrograde cholangiography (ERC), biliary stenting is recommended to prevent complications. However, the role of prophylactic biliary stenting in situations where CDL clearance has been achieved, and the patient is awaiting cholecystectomy is debatable. One retrospective study showed benefit while a small prospective study and a retrospective study did not show benefit of prophylactic biliary stenting. Moreover, a randomized controlled trial addressing this question is lacking. Hence, we planned this multicenter randomized controlled trial to study the role of a prophylactic biliary stent in recurrence of stones and biliary complications in patients awaiting cholecystectomy after biliary stone clearance.

Registry
clinicaltrials.gov
Start Date
September 30, 2023
End Date
December 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Asian Institute of Gastroenterology, India
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 18-80 years
  • Cases of cholelithiasis with concomitant CDL in whom CBD clearance is achieved will be included.

Exclusion Criteria

  • Informed consent not available
  • Patients opting for single stage surgery
  • Previous hepatobiliary surgery
  • Failure to completely clear CDL on ERC
  • Concomitant benign biliary strictures (like chronic pancreatitis, portal cavernoma cholangiopathy, post cholecystectomy, primary biliary cholangitis related)
  • Previous cholecystectomy patients
  • Associated malignancy
  • Coagulopathy(INR\>1.5, platlets\<1lac)
  • Severe cholangitis

Outcomes

Primary Outcomes

To compare the CDL recurrence rate between the 2 groups

Time Frame: 3 Months

Secondary Outcomes

  • To compare the biliary complications between the 2 groups(3 Months)
  • To compare the pancreatic complications between the 2 groups -To compare the need for repeat ERC between the 2 groups The outcomes will be compared during the time period of 3 months irrespective of the timing of cholecystectomy.(3 Months)

Similar Trials